The impact of luteal supplement on pregnancy outcome following stimulated IVF cycles

Medical Journal of Malaysia

Volumn 60, Issue 2, 2005, Pages 151-157

  Tay, Paul Yee Siang ^a   Lenton, E A ^b  

^a UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^b Sheffield Fertility Centre   (United Kingdom)

Author keywords

HCG; In vitro fertilisation; Luteal phase; Pregnancy; Progesterone

Indexed keywords

CHORIONIC GONADOTROPIN; PROGESTERONE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG FORMULATION; FEMALE; FERTILIZATION IN VITRO; HORMONE SUBSTITUTION; HUMAN; LUTEAL INSUFFICIENCY; LUTEAL PHASE; PREGNANCY OUTCOME; PROGESTERONE BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; GEL; INTRAVAGINAL DRUG ADMINISTRATION; NIDATION; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECTAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVAGINAL; ADMINISTRATION, RECTAL; ADULT; CHORIONIC GONADOTROPIN; EMBRYO IMPLANTATION; FEMALE; FERTILIZATION IN VITRO; FOLLOW-UP STUDIES; GELS; HUMANS; LUTEAL PHASE; PREGNANCY; PREGNANCY OUTCOME; PREGNANCY RATE; PROGESTERONE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 24944505643     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Tay Pys, Lenton EA. Progesterone profiles in pregnant, non pregnant natural and stimulated IVF cycles with and without luteal support. Med. J. Malaysia. 2002; 57: 178-87.
2. Sharara, FL, McClamrock HD. Ratio of oestradiol concentration on the day of human chorionic gonadotrophin administration to mid-luteal oestradiol concentration is predictive of in-vitro fertilization outcome. Hum. Reprod. 1999; 11: 2777-82.
3. Speroff L, Glass RH, Kase NG. Regulation of the menstrual cycle. In Speroff, L., Glass, R.H., Kase, N.G. (eds), Clinical Gynaecologic Endocrinology and Infertility. 5th edition, Williams and Wilkins, Baltimore, MA, USA, 1994; 1183-230.
4. Penzias AS. Luteal phase support. Fertil. Steril. 2002; 77: 318-23.
5. Penzias AS, Alper MM. Luteal support with vaginal micronized progesterone gel in assisted reproduction. Reprod. Biomed. Onl. 2003; 6: 287-95.
6. Ludwig M, Schwartz P, Babahan B, Katalinic A, Weiss JM, Felberbaum R, Al-Hasani S, Diedrich K. Luteal phase support using either Crinone 8% or Utrogest: results of a prospective, randomized study. Eur. J. Obstet. Gynecol. Reprod. Bio. 2002; 103: 48-52.
7. Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of oestradiol or progesterone. Maturitas; 1993; 16: 185-201.
8. Gurbuz B, Yalti S, Ficicioglu C, Delikara N, Alpay Z. Bleeding patterns in women using intramuscular progesterone for luteal support in in-vitro fertilisation cycles. J. Obstet. Gynaecol. 2003; 23: 267-70.
9. Trounson A, Howlett D, Rogers P, Hoppen H. The effect of progesterone supplementation around the time of oocyte recovery in patients superovulated for in-vitro fertilisation. Fertil. Steril. 1986; 45: 532-35.
10. Fulimoto A, Osuga Y, Fujiwara T, Yano T. Human chorionic gonadotropin combined with progesterone for luteal support improves pregnancy rate in patients with low late-mid luteal estradiol levels in IVF cycles. J.Asst. Reprod. Genet. 2002; 19: 550-4.
11. Segal S, Casper RF. Progesterone supplementation increases luteal phase endometrial thickness and oestradiol levels in in-vitro fertilisation. Hum Reprod. 1992; 9: 1210-13.
12. Simon JA, Robinson DE, Andrews MC, Hildebrand JR, Rocci ML, Blake RE, Hodgen GD. The absorption of oral micronised progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil. Steril. 1993; 60: 26-33.
13. Nahoul K, Dehennin L, Jondet M, Roger M. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of oestradiol or progesterone. Maturitas 1993; 16: 185-201.
14. Arafat ES, Hargrove JT, Maxson WS. Sedative and hypnotic effects of oral administration of micronised progesterone may be mediated through its metabolites. Am. J. Obstet. Gynecol., 1988; 159: 1203-209.
15. Damario MA, Goudas VT, Session DR, Hammitt DG, Dumesio DA. Crinone 8% vaginal progesterone gel results in lower embryonic implantation efficiency after in vitro fertilization-embryo transfer. Fertil. Steril.; 1999; 72: 830-6.
16. Smitz J, Devroey P, Faguer B, Bourgain C, Camus M, Van Steirteghem AC. A prospective randomised comparison of intramuscular or intravaginal natural progesterone as a luteal phase and early pregnancy supplement. Hum. Reprod. 1992; 2: 168-75.
17. Liu HC, Pyrgiotis E, Davis O, Rosenwaks Z. Active corpus luteum function at pre-, peri- and post-implantation is essential for a viable pregnancy. Ear. Preg: Bio. & Med. 1995; 281-87.
18. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil. Steril. 1994; 62: 485-90.
19. Fanchin R, De Ziegler D, Bergeron C, Righini C, Torrisi C, Frydman R. Transvaginal administration of progesterone. Obstet Gynecol 1997; 90: 396-401.
20. Cicinelli E, De Ziegler D. Transvaginal progesterone: evidence for a new functional "portal system" flowing from the vagina to the uterus. Hum Reprod Update 1999; 5: 365-72.